everyone for We quarter fourth Joe, you very for update. remarks joining listening for you this you much, appreciate your to our thank us kind joining us and morning. Thank
is the Sciences, and marketing, our Commercial XHANCE President a role our to leader a Therapeutics, Commercial commercial get successful out of team. Nestle history introduce leader, of successful Aimmune of big of organizations experience U.S. commercial business science Senior including the commercial Health lengthy as has in a access our and part Spence. market we as pharmaceuticals most I we execution was experience will and his at life of Paul Chief responsibility to update, the in new division Officer, Before would like with Paul commercial His Organization he years profiles focus nearly XX Vice -- and of and operations. for industry started be relentless commercial Pharmaceutical the why recently new with on sales, of building products brands similar recently, believe
So, presentation. We'll from moment, into takeaways starting on highlight a to today's more detail three in key I'd but go slide three. like
significant the current multifold, environment, access new larger nasal we off-label use a constrained is we us by is First, drive polyps, and audience providers times enthusiastic the than addition ten where indication in by to and about the could Claims potential patient healthcare who remain enable being of patients suggests believe payers, sinusitis. an increasingly CS chronic diagnosed healthcare frequently indication approximately have more growth. treat that to data currently therefore
chronic indication we This a drug guidance Second, treatment new was previous February for road of is with our approval application of important XHANCE consistent our the submission to potential announced the a XXXX. patients an milestone the supplemental with as in for and new on December sinusitis. in
from we cash label following our on significantly XXXX, be refocused for principles by CS, Third, that important than be return in we the patient is and to business that have treatment promotion produced believe expectations we those infrastructure diagnosis ever available XXXX enter XXXX, later XHANCE CS increase of of of successful frequency discuss reduce and will for Because of strategy approval. and polyps. first potential structured potential expansion as a to our can preserving potential while because treatment return important and and shaped potential rapid in nasal FDA expectations we the as greater our have, as during drug prioritize use differences on we the have presentation. These our in this, XHANCE for dynamics, CS a capabilities profitability the promoting to launch approved the for the to launch XHANCE following investment for the of the the will focus prevalence, payer of
by approval only approved of to four. increase treatment as has treated nasal the diagnosed product for patients We the more of are order XHANCE promoted the for believe and than for data claims of first chronic diagnosed sinusitis the Turning are whom tenfold, to an that because and FDA polyps. slide be and potential treated CS number for suggests magnitude patients currently future can
cared those significantly currently our in of scope footprint, would grow of the to commercial We expect physicians which are our our greatly the existing patients within include potential expanded potential universe by for current that activities.
the are alternative including to fact We or and future selling exploring models, of already efforts of us related engage by also being of around who XX expect outside is to patients our of selling in of up for patients number prevalence data those the recognition already clinical frequently expansion are cared per means. The optimism of diagnosis are will large CS partnerships, the that commercial current The are polyps. to patients course future modest sinusitis our efforts, be very show visits today a not other for include that of expanded universe made practice. documented commercial ways ordinary by outreach through than being claims direct gives more year physicians – that we possible, physicians frequently And a educational reach. nasal much and chronic number to necessary is coded with chronic diagnosed or In it office sinusitis. patients million diagnoses
sinusitis fact may of are important is of product most aware that documented help address one today. the you hindrances challenges addition, one routine the chief practice friction is and we diagnosis the payer payers believe to In by chronic uptake in that commonly uptake created a to of
today, a not create indication for addressing with be of which practice addition or asking primary payer The aligned behaviors do who larger in may for one endoscopy population. physicians physician patient diagnosis routinely to particularly to care an requirements new today, with polyps. the and XHANCE providers of nasal of unlabeled CF course, perform challenges a diagnosis allergists is better Specifically, current attestation is payers prescribing nasal
requires prior requires physician approximately are XX% in commercial XHANCE lives As a approximately are a of today, authorization those includes diagnosis. half a a that in and that to that attestation covers -- are reminder, that a of plan a an plan plan primary in unlabeled
are be to nasal some than diagnosis. polyps believe more physicians broadly nasal XHANCE could and a we patients could While insurance for more polyps choose require that write diagnosed patients independently with don't that being attestation plans currently to with diagnosed
or our deterring writing to constrained meaningful nasal at broadly that in Having require physicians attestation efforts many all. is of a from XHANCE are And promotional today of we polyps. course, patients number believe plans
group for physicians a it to a willing they write significant indication, we CS there's to routinely much With broader more be straightforward to that to for test believe comparatively a diagnosis potential a because today. documenting are more of patients their be will
which FDA. for promotional other nasal we uncertain treatment additional XHANCE rhinosinusitis. sinusitis, our drug with language. the ever in the of as language potential six. is Accordingly, submitted slide a novel rhinosinusitis indication this specific for a February polyps Turning is indication supplemental chronic future to indication chronic similar pursuit perspective, be From patients rhinosinusitis, or a of On chronic by may no without XX, application drug new bit view interchangeable. we of has approved been these terms and chronic This
in submission expected the start accepted, submission type mid-December in that in review date, from which Focusing standard is an this next, we result date window sNDA on the accept will to of which whether by filing. what's period the May. of would now action date, XX the FDA If for XXXX. we the a expect months FDA during occur FDA XX on application submission for to decide day are Based
review prepared and of organization and during the our our data opened in questions, the we in program the included today's to be happy a major appendix any not an summaries have Q&A for will to are session. with the endpoints landmark reopen I for accomplishment We address field. however, those co-primary there during from detail we'll If remarks, presentation. program
Turning to eight. slide
year organization our how with operate Accordingly, to in plan While XXXX were call, as forward. we set we've expectations last to the as made quarter satisfied these changes were that aligned with to well full and fourth moving our are our results. we not significant results
total reducing programs. and investments expenses on initial productive already territories concentrating for our will commercial our most implemented, while Our on changes focus growth
we the our our energetically are Officer, on strategic and evaluating the acting that Commercial an on taken revenue addition, coming a on quality underlie challenge In factors both second his during new Paul variety XXXX. Spence, the on with trends Chief a He's of observed and half number improving and team key believe of of and tactical of eye the commercial execution potential months. changes in this
revenue, to size in receiving is and converted prior the the fill distribution our active our and management drive rate areas authorization of implementation of the program examples attention co-pay Specific is our prescriptions with of that improving and include payer and at efficiency the pharmacy paperwork net the physician which strategy. prescribing XHANCE interest network structure submitted, which
are is these how team only nasal considering aware in polyps for of year areas and for indication. other commercial in the also up that evaluating potential launch this Our ramifications the for XXXX, new our organization setting CS promotional have where and action not larger we successful are we much a efforts but
note to of evidence like we commercial the we'll improvement I'd that looking for changes outlook full to our be before our allow year influence performance XXXX. for
XXXX. in XXXX, new fourth to X% compared XX,XXX XHANCE, approximately prescriptions results, quarter a were As decrease there fourth for quarter for of
X% increased any a While prescriptions large a market which component the condition, same defined by period. by rhinitis by prescriptions physician any for of our INS allergic over for written
year a market XXXX, described there year while over the to I compared full X% increase full XXX,XXX approximately for were increased new just the slight same prescriptions period. INS XHANCE, For XXXX, by the
to In a quarter prescriptions Turning same written physician the which condition, of XX,XXX by XXXX, any our prescriptions component for there for while XXXX, large by increased nine. market, which were allergic over quarter slide approximately a fourth any X% INS to compared period. prescriptions the fourth of total X% rhinitis includes for decrease XHANCE,
XHANCE, full INS full XXXX, prescriptions market a same approximately X% total for period. while there over by described increase the increased For to year compared the year previously XXX,XXX were XXXX, the X%
X.X% in fourth in when XXXX. denominator quarter this this market fraction will share replace Turning we may the decreased the In to X.X% compared future, fourth to to measure slide XXXX share XX. or eliminate used of because quarter XHANCE the of has calculate limitations. be
does for denominator which share written indicated XX,XXX rhinitis the prescriptions audience intranasal prescriptions a for as allergic steroid As several and indications number for polyps. nasal physicians, all to of substantial includes such include prescriptions biologics treat this not an which of reminder, includes a are the by that approximately
results as Breadth number physicians and XHANCE prescribing mixed patients physician have fourth XXXX total quarter quarter from depth filling of by the measured of fourth XXXX. had who to prescriptions
increase fill there quarter Regarding X,XXX XXXX, XHANCE, fourth fourth in who breadth, a of compared had an of prescription XXXX. least for of physicians at one were quarter X% patient to
Regarding by by approximately X,XXX XXXX depth, physicians quarter, this XXXX the X% from number filled more fourth quarter patients had than XX segment. fourth XHANCE a to of in decreased their who with quarter prescriptions in physicians
turn now fourth discuss call and performance over quarter the year to will financial to guidance. Jonathan full I and
